18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
NCT05520255
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
2800
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
18F-PSMA-1007
Sponsor
University of Alberta